Good MorningEquities started Wednesday on solid footing rising more than 1.0% ahead of the FOMC meeting. The weaker-than-expected CPI gave the market some hope the Fed would give some relief and those hopes were dashed. While the Fed hiked rates by only 50 basis points the new statement indicated the peak of interest rates will likely be over 5.0% and remain at that level into 2023. This news caused the market to reverse course and the S&P 500 shed 0.60% at the close of the session.
The next hurdle for the market is the PCE price index which comes out next Friday. If the index confirms a downtrend in the pace of inflation it could send the market soaring and usher in the Santa Claus Rally. If not, the market could be in for a rough holiday as traders and investors begin to position for what could be a very bad year for stocks. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Energy | |
Enterprise Products Partners (NYSE: EPD) has recently been on a wild ride. It has gone thru some stunning peaks and troughs and ended up 7.82% year to date. As a result, investors might wonder if its current stock price represents a good entry for buying shares.
So let's examine the bull and... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
Latin American e-commerce specialist MercadoLibre Inc. (NASDAQ: MELI) has only trended lower in 2022, and a new partnership could boost the stock.
Earlier this month, the chief financial officer of the Argentina-based company told Reuters that MercadoLibre would begin processing business payments... Read the Full Story |
|
Healthcare | |
U.S. mid-cap stocks are on pace to outperform their large-cap peers for the second straight year. The S&P 400 is down 13% year-to-date, a roughly 400 basis points edge over the S&P 500.
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Companies are... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Consumer Discretionary | |
Updated - December 14, 2022– via InvestorWire – Mullen Automotive, Inc., an emerging electric vehicle (“EV”) manufacturer, announces today that it has entered into a definitive agreement with Loop Global Inc. ("Loop"), a full-service EV charging solution provider, to build ... Read the Full Story |
|
Industrials | |
REV Group (NYSE: REVG) has been struggling with supply chain issues and economic woe just like everybody else but now the stock is ready to make a major reversal. The company’s Q4 results and guidance for the year were better than expected and supported by the company’s diverse operati... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | |
After a brutal year in the semiconductor space, things are starting to look up as we round the corner into 2023. Two of the better-known names to emerge as leaders in recent years, NVIDIA Corporation (NASDAQ: NVDA) and Advanced Micro Devices, Inc. (NASDAQ: AMD) have both seen their shares rally th... Read the Full Story |
|
Markets | |
Biotech stocks are often among the market’s most volatile, and Harpoon Therapeutics Inc. (NASDAQ: HARP) offers a perfect example of that.
The stock rocketed to an eight-month high Monday, advancing as much as 191% intraday before settling down to a gain of 22.61%. Shares closed at $1.41 Mon... Read the Full Story |
|
Materials | |
Queen’s legendary 1977 rock anthem “We Are the Champions” was once deemed by scientists to be the catchiest song in popular music history. To this day, it is often heard in crowning moments at sports stadiums and in upbeat TV advertisements.
In the investment world, Freddy Mercu... Read the Full Story |
|
Healthcare | |
DexCom, Inc. (NASDAQ: DXCM) is a continuous glucose monitoring (CGM) company. In early December, they received approval from the United States Food and Drug Administration (FDA) for their new monitor, the G7. This device assists patients with Type 1 and Type 2 diabetes and gestational diabetes. Fu... Read the Full Story |
|
Consumer Discretionary | |
Premium retail department store chain Nordstrom, Inc. (NYSE: JWN) stock has fallen (-27%) in 2022. It’s recent earnings beat was overshadowed by falling YoY metrics. The sell-off was accelerated after bearish comments were made by CEO Erik Nordstrom at the Morgan Stanley Consumer & Retai... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. | | View Today's Stock Pick |
|
